Rite Aid (NYSE:RAD) investors had a rough day, with shares cratering 7% after the pharmacy lowered its full-year guidance and reported that it anticipated only $0.04 per share in earnings versus analyst estimates of $0.08 per share. The sell-off felt a little extreme given the stock's stunning turnaround over the past several years.

But then again, competitor Walgreen (NASDAQ:WBA) reported better news, indicating that perhaps Rite Aid isn't executing as well in this competitive pharmacy environment.

So, was Rite Aid's sell-off overdone? In the video below, from Thursday's Market Checkup, the Motley Fool's health care-focused investing show, health care analysts Michael Douglass and David Williamson give their take.